Mirador Capital Partners LP Has $3.41 Million Position in Cytokinetics, Incorporated (NASDAQ:CYTK)

Mirador Capital Partners LP raised its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) by 2.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 64,626 shares of the biopharmaceutical company’s stock after acquiring an additional 1,483 shares during the quarter. Mirador Capital Partners LP owned about 0.06% of Cytokinetics worth $3,412,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Cytokinetics by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,016,889 shares of the biopharmaceutical company’s stock valued at $919,800,000 after purchasing an additional 273,565 shares during the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of Cytokinetics in the 2nd quarter valued at approximately $246,074,000. Integral Health Asset Management LLC boosted its stake in Cytokinetics by 122.2% during the 2nd quarter. Integral Health Asset Management LLC now owns 1,000,000 shares of the biopharmaceutical company’s stock worth $54,180,000 after acquiring an additional 550,000 shares during the last quarter. Hood River Capital Management LLC grew its holdings in Cytokinetics by 5.9% during the second quarter. Hood River Capital Management LLC now owns 737,637 shares of the biopharmaceutical company’s stock valued at $39,965,000 after purchasing an additional 40,990 shares during the period. Finally, Westfield Capital Management Co. LP bought a new stake in Cytokinetics in the first quarter valued at approximately $51,277,000.

Cytokinetics Price Performance

NASDAQ CYTK traded up $0.97 on Friday, hitting $56.68. 1,190,130 shares of the company’s stock were exchanged, compared to its average volume of 2,211,548. Cytokinetics, Incorporated has a 52 week low of $26.55 and a 52 week high of $110.25. The stock has a 50-day moving average of $55.41 and a 200-day moving average of $58.47. The company has a current ratio of 10.39, a quick ratio of 10.39 and a debt-to-equity ratio of 5.93. The stock has a market cap of $5.94 billion, a price-to-earnings ratio of -10.50 and a beta of 0.77.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.25). The company had revenue of $0.25 million during the quarter, compared to analyst estimates of $7.61 million. The firm’s quarterly revenue was down 71.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.34) earnings per share. Analysts expect that Cytokinetics, Incorporated will post -5.15 earnings per share for the current year.

Insider Buying and Selling at Cytokinetics

In other news, EVP Fady Ibraham Malik sold 7,300 shares of the company’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $55.90, for a total transaction of $408,070.00. Following the completion of the transaction, the executive vice president now directly owns 131,004 shares in the company, valued at approximately $7,323,123.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Cytokinetics news, Director B Lynne Parshall sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $55.82, for a total transaction of $279,100.00. Following the sale, the director now directly owns 20,600 shares of the company’s stock, valued at $1,149,892. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Fady Ibraham Malik sold 7,300 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $55.90, for a total transaction of $408,070.00. Following the completion of the transaction, the executive vice president now owns 131,004 shares of the company’s stock, valued at approximately $7,323,123.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 96,084 shares of company stock worth $5,360,766 over the last quarter. Corporate insiders own 3.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a report on Tuesday, September 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Cytokinetics in a report on Monday, September 9th. The Goldman Sachs Group downgraded shares of Cytokinetics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $85.00 to $60.00 in a report on Tuesday, August 13th. JPMorgan Chase & Co. upped their price target on shares of Cytokinetics from $65.00 to $71.00 and gave the company an “overweight” rating in a report on Thursday, September 5th. Finally, HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Cytokinetics in a report on Monday, September 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and a consensus price target of $80.67.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.